Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label Study to Assess the ~32-Year Persistence of Hepatitis A Antibody Among Participants in the Pivotal, Double-Blind, Placebo-Controlled Efficacy Study of VAQTA (Study 023-001)

NCT06184230 is registered in ClinicalTrials.gov with Best Healthcare Inc. as lead sponsor.

NCT NCT06184230
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06184230 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label Study to Assess the ~32-Year Persistence of Hepatitis A Antibody Among Participants in the Pivotal, Double-Blind, Placebo-Controlled Efficacy Study of VAQTA (Study 023-001)
Lead sponsor
Best Healthcare Inc.
Phase
Phase 4
Overall status
Unknown status
Start date
January 31, 2024
Completion date
June 30, 2025
Enrollment
300 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis a